{
  "abstract": "Background\n\nPeople living with HIV (PLWH) have increased cardiovascular disease risk, and dyslipidemia remains a major modifiable factor. Achieving recommended low-density lipoprotein cholesterol (LDL-C) targets can be challenging.Objective\n\nTo evaluate the real-world effectiveness and safety of fixed-dose low-dose rosuvastatin/ezetimibe in virologically stable PLWH and to describe lipid-lowering kinetics in comparison with an HIV-negative control cohort.Methods\n\nThis retrospective single-center study included 32 PLWH and 43 HIV-negative outpatients receiving rosuvastatin 5 mg plus ezetimibe 10 mg daily. Lipid parameters, cardiovascular risk scores, and safety markers were assessed at baseline, 3 months, and 6 months.Results\n\nIn PLWH, LDL-C decreased from 170.7 ± 35.1 to 87.8 ± 24.6 mg/dL at 6 months, corresponding to a mean reduction of 46.7% (p < 0.001). Total cholesterol and non-HDL cholesterol also decreased significantly (p < 0.001 for both), while triglycerides decreased significantly at month 6 (p = 0.016). Overall, 53.1% of PLWH reached guideline-recommended LDL-C targets. Both the 5-year and 10-year D:A:D scores decreased significantly during follow-up (p < 0.001 for both). The exploratory comparison suggested a more rapid early lipid response among HIV-negative controls, with most of the reduction occurring by month 3. No treatment-limiting adverse events or viro-immunological deterioration occurred.Conclusions\n\nLow-dose rosuvastatin combined with ezetimibe was associated with substantial improvement in atherogenic lipid parameters in virologically stable PLWH, while the exploratory finding of an earlier response among HIV-negative controls may support further investigation of treatment-response kinetics.",
  "abstract_shown": true,
  "affiliations": [
    "Clinic of Infectious Diseases, Department of Medicine and Aging Science, \"G. d'Annunzio\" University of Chieti-Pescara, 66100 Chieti, Italy.",
    "Infectious Disease Clinic, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.",
    "Institute of Internal Medicine, Department of Medicine and Aging Science, \"G. d'Annunzio\" University of Chieti-Pescara, 66100 Chieti, Italy."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Katia Falasca",
      "orcid": "0000-0002-8795-5410"
    },
    {
      "affs": [
        1
      ],
      "name": "Claudio Ucciferri",
      "orcid": "0000-0002-5866-3849"
    },
    {
      "affs": [
        2
      ],
      "name": "Damiano D'Ardes",
      "orcid": "0000-0001-5573-4536"
    },
    {
      "affs": [
        0
      ],
      "name": "Raffaele Ferri",
      "orcid": "0009-0002-6739-3913"
    },
    {
      "affs": [
        0
      ],
      "name": "Livia Moffa"
    },
    {
      "affs": [
        0
      ],
      "name": "Francesca Chiappini"
    },
    {
      "affs": [
        2
      ],
      "name": "Riccardo Mattia Ricciardi",
      "orcid": "0009-0008-4998-860X"
    },
    {
      "affs": [
        2
      ],
      "name": "Francesco Cipollone"
    },
    {
      "affs": [
        0
      ],
      "name": "Jacopo Vecchiet",
      "orcid": "0000-0001-9250-4844"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9r59eg4nnqrke.bib",
  "cited_by": 0,
  "doi": "10.3390/idr18050119",
  "fulltext_url": "https://europepmc.org/articles/PMC13704494",
  "id": "9r59eg4nnqrke",
  "issns": [
    "2036-7430",
    "2036-7449"
  ],
  "landing_url": "https://europepmc.org/article/MED/42930510",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2746|Lipoproteins and Cardiovascular Health"
    ]
  ],
  "openalex": "W7222560905",
  "pdf_url": "https://europepmc.org/articles/PMC13704494?pdf=render",
  "pmcid": "PMC13704494",
  "pmid": "42930510",
  "published": "2026-10-16",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/9r59eg4nnqrke.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:01Z",
      "native_id": "MED:42930510",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42930510"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Lipoproteins and Cardiovascular Health",
      "subfield": "surgery"
    }
  ],
  "title": "Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.",
  "title_text": "Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:01Z",
  "url": "https://research.draconitic.com/paper/9r59eg4nnqrke",
  "venue": "Infectious disease reports",
  "versions": []
}